Agent for preventing or reducing pigmentation

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the chemical-pharmaceutical industry and represents an agent for preventing or reducing pigmentation, containing a compound presented by the following formula (1) its stereoisomer and/or its pharmacologically acceptable salt, wherein: R1 represents a hydrogen atom or an alkyl group with a linear or branched chain having 1-4 carbon atoms; R2 represents a hydrogen atom or an unsubstituted aliphatic hydrocarbon group having 1-4 carbon atoms; R3 represents an unsubstituted aromatic group having 5-15 carbon atoms, substituted by an alkyl group having 1-6 carbon atoms, by an alkoxy group containing an alkyl chain having 1-6 carbon atoms, or by a phenyl group; R3 also represents an aromatic group having 5-15 carbon atoms; n is equal to 1 or 2, and m represents an integer falling within 0 to 3.

EFFECT: preparing the agent for preventing or reducing pigmentation.

10 cl, 10 ex, 6 tbl

 

The technical field to which the invention relates

The present invention relates to a preparation for external use on the skin, which preferably is suitable for cosmetic preparations (including preventive and curative cosmetics). In particular, the present invention relates to a preparation for external use on the skin, which is characterized in that it contains an agent for the prevention or reduction of pigmentation, containing the compound represented by the following General formula (1), its isomer and/or its pharmacologically acceptable salt.

[where R1represents a hydrogen atom or alkyl group with a linear or branched chain having 1-8 carbon atoms, R2represents a hydrogen atom, substituted or unsubstituted aliphatic hydrocarbon group having 1-8 carbon atoms, a substituted or unsubstituted aromatic group, a substituted or unsubstituted condensed polycyclic aromatic group or a substituted or unsubstituted heterocyclic group having 5 to 12 carbon atoms, R3is a substituted or unsubstituted aromatic group, a substituted or unsubstituted condensed polycyclic aromatic group or a substituted or unsubstituted heterocyclics�a second group, having 5-15 carbon atoms, n is an integer equal to 1 or 2 and m is an integer from 0 to 3].

Art

For example, pigmentation, freckles, melasma and senile lentigo, which occur on skin after sun exposure, are such States that production of melanin is very much easier due to the activation of pigment cells (melanocytes) in the skin. A component that, as we know, has the function of preventing or reducing the onset and worsening problems with the pigments of the skin, as described above, is a compound (a whitening agent for the skin) that has the function of whitening skin, comprising, for example, derivatives of ascorbic acid, hydrogen peroxide, colloidal sulfur, glutathione, hydroquinone and catechol (see, for example, non-patent document 1 and non-patent document 2). Drugs for external use on the skin, which are mixed with the components as described above, are widely used as active ingredients. Currently, it is reported about the various mechanisms of action, mechanism of action, which has a compound known as a whitening agent for the skin, including, for example, the inhibitory action of the tyrosinase enzyme, degradation of tyrosinase-related protein, and the inhibition of melanin transfer�, caused by suppression of dendritic elongation in the melanocyte. There are target molecules relative to the respective mechanisms of action. To obtain expressed a strong bleaching effect on the skin, usable is an organic low molecular weight compound that properly interacts with the target molecule. In addition, low molecular weight organic compound which suitably communicates with each of the target molecules, has structural characteristics that differ depending on each of the target molecules. For this reason, ongoing research regarding the optimization of the chemical structure, for use in the maximum degree of pharmacological activities exhibited low molecular weight organic compound. Currently studies of bleaching agents for the skin are not limited to compounds which have high efficiency and high selectivity in relation to the existing target molecule, and studies, for instance, compounds that simultaneously act on multiple target molecules for skin whitening, and compounds that have a novel mechanism of action. Strong whitening effect for the skin is expected to bleaching agent� for skin as described above. In fact, carry out screening in relation to compounds having an excellent function of whitening skin, at the same time, searching suitable for compounds that have different chemical structure or pharmacological characteristics. Any bleaching agent for skin that has a new basic structure is still in demand even now.

The proteins that make up living organism, composed of 20 types of α-amino acids with different side chains, which are called "essential amino acids", in almost all cases. Reported various biological activities for α-amino acids described above, in addition to the functions that they are biological components. In addition, methionine and cysteine, which are included in α-amino acids described above, and each of which has a sulfur atom in the chemical structure, expected to have any biological activity resulting from the characteristics of the sulfur atom, distinct from α-amino acids, and they are applied in various fields, including, for example, pharmaceuticals, cosmetics and food products. In particular, in the field of cosmetics, reported on their use, for example, as a reducing component for hair (see,for example, Patent document 1) and as a moisturizing component (e.g., see Patent document 2), in relation to the preparations for external use on the skin, mix with methionine and cysteine. Thus, n-acetyl-L-cysteine, which is a derivative of cysteine, is metabolized in the form of glutathione, which is an antioxidant. For this reason, n-acetyl-L-cysteine is used as an additive. However, when such a derivative of α-amino acid that contains a sulfur atom in the molecular structure, is used for example in cosmetic preparation, a problem arises, for example, that the amino acid or composition, such as the preparation for external use on the skin, is unstable, and there is an unpleasant smell caused by the products of its decomposition. On the other hand, it is known that cysteine acid and any derivative having an aliphatic acyl group on the nitrogen atom, is, for example, the activity of oil-soluble material basis (e.g., see Patent document 3), a surfactant (e.g., see Patent document 4), dissolve mucus and function of an antioxidant (e.g., see Patent document 5). Furthermore, it is known that n-benzyl derivative of cysteine acid has the function of an antioxidant (e.g., see Patent document 6).However, to the knowledge of the authors of the present invention, it is not known that the compound represented by the General formula (1) described above, its isomer and/or its pharmacologically acceptable salt was/had the effect of preventing or reducing the pigmentation. In addition, to the knowledge of the authors of the present invention, it is not known that the compound had good solubility in hydrophilic or lipophilic environment that the connection was extremely stable in forms of the compounds and pharmaceutical preparation, and connection to virtually any unpleasant smell when the connection is used in cosmetic preparation, such as preparation for external use on the skin or something like that.

Previous technical documents

Patent documents:

Patent document 1: JP2005-162699A;

Patent document 2: JP2004-323401A;

Patent document 3: JP05-117295A;

Patent document 4: JP2002-145736A;

Patent document 5: JP2005-530883A;

Patent document 6: JP11-343235A.

Non-patent documents:

Non-patent document 1: "Usefulness of Cosmetic, Evaluation Techniques and Future Overview", supervised by Katsuhiko TAKEDA, published by YAKUJI NIPPO LIMITED (2001);

Non-patent document 2: Takayuki Omori, FRAGRANCE JOURNAL, extra (special) issue No. 14, 1995, 118-126.

Summary of the invention

The present invention is carried out under such �circumstances, as described above, its purpose is the receiving agent for the prevention or reduction of pigmentation, with a new primary structure that is preferably suitable for the prevention or reduction of pigmentation, and a preparation for external use on the skin, which contains it as a component.

Considering the above circumstances, the authors of the present invention have repeatedly made vigorous attempts in search of a new agent for the prevention or reduction of pigmentation, preferably suitable for use for cosmetic product (provided that a cosmetic product includes preventive and curative cosmetics). As a result, found that the compound represented by the General formula (1) described above, its isomer and/or its pharmacologically acceptable salt is/are excellent in effect of preventing or reducing the pigmentation. Thus, completed the present invention. The present invention is as follows.

<1> Agent for the prevention or reduction of pigmentation, containing the compound represented by the following General formula (1), its isomer and/or its pharmacologically acceptable salt:

[where:

R1represents a hydrogen atom or a�kilou group with a linear or branched chain, having 1-8 carbon atoms;

R2represents a hydrogen atom, substituted or unsubstituted aliphatic hydrocarbon group having 1-8 carbon atoms, a substituted or unsubstituted aromatic group, a substituted or unsubstituted condensed polycyclic aromatic group or a substituted or unsubstituted heterocyclic group having 5 to 12 carbon atoms;

R3is a substituted or unsubstituted aromatic group, a substituted or unsubstituted condensed polycyclic aromatic group or a substituted or unsubstituted heterocyclic group having 5-15 carbon atoms;

n is an integer equal to 1 or 2 and m is an integer from 0 to 3.]

<2> Agent for the prevention or reduction of pigmentation, as defined in <1>, where in the General formula (1);

R1represents a hydrogen atom or alkyl group with a linear or branched chain having 1-8 carbon atoms;

R2represents a hydrogen atom;

R3is a substituted or unsubstituted aromatic group, a substituted or unsubstituted condensed polycyclic aromatic group or a substituted or unsubstituted heterocyclic group having 5-15 carbon atoms;

n represents the FDS�nd an integer equal to 1 or 2 and m is an integer from 0 to 3.

<3> Agent for the prevention or reduction of pigmentation, as defined in <1> or <2>, where in the General formula (1);

R1represents a hydrogen atom or alkyl group with a linear or branched chain having 1-8 carbon atoms;

R2represents a hydrogen atom;

R3is a substituted or unsubstituted aromatic group, a substituted or unsubstituted condensed polycyclic aromatic group or a substituted or unsubstituted heterocyclic group having 5-15 carbon atoms;

n is an integer equal to 1 or 2, and m represents 0.

<4> Agent for the prevention or reduction of pigmentation, as defined in any one of items <1>-<3>, where in the General formula (1);

R1represents a hydrogen atom or alkyl group with a linear or branched chain having 1-8 carbon atoms;

R2represents a hydrogen atom;

R3is a substituted or unsubstituted aromatic group, a substituted or unsubstituted condensed polycyclic aromatic group or a substituted or unsubstituted heterocyclic group having 5-15 carbon atoms;

n is 1 and m is 0.

<5> Agent for the prevention or reduction of pigmentation as defined in any of items &t; 1>-<3>, where the connection represented by the General formula (1) is a n-(o-toluoyl)cysteine acid (Compound 1), n-(m-toluoyl)cysteine acid (Compound 2), n-(p-toluoyl) cysteine acid (Compound 3), n-(p-methoxybenzoyl)cysteine acid (Compound 4), n-(4-phenylbenzyl)cysteine acid (Compound 5), n-(p-toluoyl)homocysteinemia acid (Compound 6), its isomer and/or its pharmacologically acceptable salt:

N-(o-toluoyl)cysteine acid (Compound 1);

N-(m-toluoyl)cysteine acid (Compound 2);

N-(p-toluoyl)cysteine acid (Compound 3);

N-(p-methoxybenzoyl)cysteine acid (Compound 4);

N-(4-phenylbenzyl)cysteine acid (Compound 5);

N-(p-toluoyl)homocysteinemia acid (Compound 6).

<6> the Drug is for external use on the skin, containing the agent for the prevention or reduction of pigmentation, as defined in any one of items <1>-<5>.

<7> Preparation for external use on the skin, as defined in <6>, which contains from 0.001% wt. up to 20% of the mass. agent for the prevention or reduction of pigmentation in relation to the total number of prep�rata for external use on the skin.

<8> the Drug is for external use on the skin, as defined in <6> or <7>, where the preparation for external use on skin is a cosmetic product (provided that included preventive and curative cosmetics).

<9> the Drug is for external use on the skin, for skin whitening containing the compound represented by the General formula (1), its isomer and/or its pharmacologically acceptable salt.

<10> the Connection represented by the General formula (1), as defined above, a compound as defined in <2>-<5>, as defined above, an isomer and/or their pharmacologically acceptable salts for the prevention or reduction of pigmentation.

<11> Method for the prevention or reduction of pigmentation, including the application of compounds represented by the General formula (1), as defined above, the compounds defined in <2>-<5>, as defined above, its isomer and/or its pharmacologically acceptable salt, the object for which prevention or reduction of pigmentation.

Method of carrying out the invention

<Agent for the prevention or reduction of pigmentation as the main component of the preparation for external use on skin of the present invention>

The preparation for external use on skin of the present invention is characterized in that the drugs� for external use on the skin contains an agent for the prevention or reduction of pigmentation, containing the compound represented by the General formula (1) described above, its isomer and/or its pharmacologically acceptable salt. The impact of an agent for preventing or reducing the pigmentation of the present invention also includes preventing the formation of pigmentation in the future, in addition to the impact of suppressing pigmentation, pigmentation when already formed, is reduced or eliminated. As an agent for preventing or reducing the pigmentation of the present invention is any suitable component, without any special restriction, provided that the component is in the connection represented by the General formula (1) described above, its isomer and/or its pharmacologically acceptable salt, and the component has the effect of preventing or reducing the pigmentation. However, more preferably, can be suitably illustrate the component that has the effect of suppressing the pigmentation in the study of suppression of pigmentation caused by ultraviolet radiation, with the use of Guinea pigs", as described later. A component that has the effects of suppressing pigmentation, the study of inhibition of pigmentation, as described above, means the component for which the effect of suppressing the pigmentation is confirmed in group�e, which introduces a substance that should be evaluated in comparison with the control group (control group with the solvent). More preferably, relevant the receiving component, which is confirmed by the statistically significant difference in the effects of suppression of pigmentation in relation to the group, which introduces a substance that should be evaluated in comparison with the control group.

Now will be described the connection represented by the General formula (1), its isomer and/or its pharmacologically acceptable salt. In the formula, R1represents a hydrogen atom or alkyl group with a linear or branched chain having 1-8 carbon atoms; R2represents a hydrogen atom, substituted or unsubstituted aliphatic hydrocarbon group having 1-8 carbon atoms, a substituted or unsubstituted aromatic group, a substituted or unsubstituted condensed polycyclic aromatic group or a substituted or unsubstituted heterocyclic group having 5 to 12 carbon atoms; R3is a substituted or unsubstituted aromatic group, a substituted or unsubstituted condensed polycyclic aromatic group or a substituted or unsubstituted heterocyclic group having 5-15 carbon atoms; n represents with�fight integer, is 1 or 2, and m is an integer from 0 to 3.

R1as described above, represents a hydrogen atom or alkyl group with a linear or branched chain having 1-8 carbon atoms, more preferably having 1-4 carbon atoms. Specific examples can preferably be illustrated, for example, a hydrogen atom, a methyl group, an ethyl group, a n-propyl group, isopropylene group, n-butyl group, isobutylene group, sec-butyl group, tert-butyl group, n-Pintilei group, isopentyl group, neopentyl group, tert-Pintilei group 1-methylbutyl group, n-hexylene group, 1-methylpentyl group, n-heptylene group and n-aktiline group. More preferably, they can be suitably illustrated by a hydrogen atom, a methyl group and an ethyl group.

R2represents a hydrogen atom, substituted or unsubstituted aliphatic hydrocarbon group having 1-8 carbon atoms, more preferably having 1-4 carbon atoms, a substituted or unsubstituted aromatic group, a substituted or unsubstituted condensed polycyclic aromatic group or a substituted or unsubstituted heterocyclic group having 5 to 12 carbon atoms. In regard to the Deputy, his �can preferably be illustrated, for example, an alkyl group having 1-6 carbon atoms, more preferably having 1-4 carbon atoms, alkoxy group having an alkyl chain having 1-6 carbon atoms, more preferably having 1-4 carbon atoms, alkoxyalkyl group (preferably consisting of alkoxy groups having an alkyl chain having 1-4 carbon atoms, and alkyl group having 1-4 carbon atoms), an aromatic or polycyclic condensed aromatic group which may have an alkyl group having 1-4 carbon atoms, or alkoxy group, having 1-4 carbon atoms (aromatic group or polycyclic condensed aromatic group preferably represents a phenyl group or naftalina group, and hydroxy group.

With respect to the group represented by R2concrete examples can preferably be illustrated, for example, a hydrogen atom, methyl group, ethyl group, propyl group, butyl group, Pintilei group, hexylene group, heptylene group, octillo group, hydroxyethylene group, hydroxypropyl group, phenyl group, methylphenylene group, ethylenimine group, propylaniline group, methoxyphenyl group, ethoxyphenyl group, propylhexedrine group, benzyl group, IU�albaniles group ethylbenzene group, propylaniline group, methoxybenzyl group, ethoxybenzyl group, propylhexedrine group, phenylethylene group, methylphenylethyl group, ethylenebutylene group, propyleneamine group, methoxyphenylalanine group, ethoxybenzylidene group, populatefedoraroles group, naftilos group, methylnaphthalenes group, ethylnaphthalene group, methoxynaphthalene group, ethoxyethylene group, naphthylmethyl group, methylnaphthalenes group, ethylnaphthalene group, methoxynaphthalene group, methoxynaphthalene group, ethoxyethylene group, naphthylethylene group, methylnaphthalenes group, ethylnaphthalene group, methoxynaphthalene group, ethoxymethyleneamino group and biphenyl group. More preferably, it can be suitably illustrated by a hydrogen atom, methyl group, ethyl group and benzyl group.

R3is a substituted or unsubstituted aromatic group, a substituted or unsubstituted condensed polycyclic aromatic group or a substituted or unsubstituted heterocyclic group having 5 to 15 carbon atoms. In regard to the Deputy, it can preferably be illustrated, �of primer, an alkyl group having 1-6 carbon atoms, more preferably having 1-4 carbon atoms, alkoxy group having an alkyl chain having 1-6 carbon atoms, more preferably having 1-4 carbon atoms, alkylamino having alkyl chain (chain) having 1-6 carbon atoms, more preferably having 1-4 carbon atoms, halogen atom, halogenated alkyl group (preferably having an alkyl chain having 1-4 carbon atoms), hydroxy-group and amino group.

With respect to the group represented by R3concrete examples can preferably be illustrated, for example, peredelnoj group, methylpyridyl group, ethylpyridine group, propylpyridine group, methoxypyridine group, ethoxypyridine group, propylhexedrine group, hydroxypyridine group, aminopyridine group, n-methylaminopropyl group, n-ethylenepropylene group, N,N,-dimethylaminopyridine group, N,N,-diethylaminophenyl group, chloropyridine group, forberedelse group, diferencijalno group, triftormetilfullerenov group, phenyl group, methylphenylene group, ethylenimine group, propylaniline group, methoxyphenyl group, ethoxyphenyl group, propylhexedrine group, hydroxyphenyl�Oh group, aminoaniline group, n-methylaminophenol group, n-acylaminopenicillins group, N,N,-dimethylaminophenyl group, N,N-diethylaminophenyl group, chloraniline group, fluorophenyl group, defterlerini group, triftormetilfullerenov group, naftilos group, methylnaphthalenes group, ethylnaphthalene group, propylheptyl group, methoxynaphthalene group, ethoxyethylene group, propylhexedrine group, hydroxynaphthyl group, aminonaphthalene group, n-methylaminomethyl group, n-ethylaminomethyl group,N,N-dimethylaminomethylene group, N,N-Diethylaminoethanolgroup chloronaphthalene group, tomatillos group, definateley group, triftormetilfullerenov group, biphenyl group, methylpiperidino group, ethylbiphenyl group, methoxybiphenyl group and ethoxymethylene group. More preferably, it is possible to appropriately illustrate peredelnoj group, phenyl group, methylphenylene group, ethylenimine group, methoxyphenyl group, ethoxyphenyl group, fluorophenyl group, triftormetilfullerenov group, naftalina group and biphenyl group.

The number of substituents on the aliphatic hydrocarbon group, an aromatic group, a condensed polycyclic�iravani aromatic group or heterocyclic group may preferably be illustrated as 0-3, and more preferably, this amount is 0 or 1. One or more substituents as described above, can exist independently, respectively, as a Deputy (deputies) for the aliphatic hydrocarbon group, an aromatic group, a condensed polycyclic aromatic group or heterocyclic group.

As described above, n is an integer equal to 1 or 2, and m is an integer from 0 to 3.

Compound is preferably suitable for use as compounds represented by the General formula (1) described above, can preferably be illustrated by the compound defined in <2> as described above, its isomer and/or its pharmacologically acceptable salt. Compounds suitable for use, more preferably, may be illustrated by the compound defined in <3> as described above, its isomer and/or its pharmacologically acceptable salt. Compounds suitable for use, even more preferably, can preferably be illustrated by the compound defined in <4> as described above, its isomer and/or its pharmacologically acceptable salt. Preferred compounds included in the compound represented by the General formula (1) described above, and the connections defined in <2>-<4>, con�are illustrated with specific n-(o-toluoyl)cysteine acid (Compound 1), n-(m-toluoyl)cysteine acid (Compound 2), n-(p-toluoyl)cysteine acid (Compound 3), n-(p-methoxybenzoyl)cysteine acid (Compound 4), n-(4-phenylbenzyl)cysteine acid (Compound 5), n-(p-toluoyl)homocysteinemia acid (Compound 6), isomer and/or their pharmacologically acceptable salt. Compounds as described above have an excellent effect of preventing or reducing the pigmentation. In addition, the compounds are excellent in the solubility in hydrophilic or lipophilic solvent, and is simple obtaining a pharmaceutical product, such as the preparation for external use on the skin or something like that. In addition, the compounds are excellent in retention on the skin and on the stability of pharmaceutical preparation, the compounds do not cause odor, which prevents the realization of the product, and the compounds show excellent exposure to prevent or reduce pigmentation.

Now will be described the connection defined in <2> described above. In the formula, R1represents a hydrogen atom or alkyl group with a linear or branched chain having 1-8 carbon atoms; R2represents a hydrogen atom; R3is a substituted or unsubstituted aromatic group, substituted or asamese�ing condensed polycyclic aromatic group or a substituted or unsubstituted heterocyclic group, having 5-15 carbon atoms; n is an integer equal to 1 or 2 and m is an integer from 0 to 3.

R1as described above, represents a hydrogen atom or alkyl group with a linear or branched chain having 1-8 carbon atoms. Specific examples can preferably be illustrated, for example, hydrogen atom, methyl group, ethyl group, propyl group, butyl group, Pintilei group, hexylene group, heptylene group and aktiline group. More preferably, it can be suitably illustrated with the help of a hydrogen atom, methyl group and ethyl group.

R3as described above, represents a substituted or unsubstituted aromatic group, a substituted or unsubstituted condensed polycyclic aromatic group or a substituted or unsubstituted heterocyclic group having 5 to 15 carbon atoms. In regard to the Deputy, preferably, it can be illustrated, for example, an alkyl group having 1-6 carbon atoms, more preferably having 1-4 carbon atoms, alkoxy group having an alkyl chain having 1-6 carbon atoms, more preferably having 1-4 carbon atoms, alkylamino group having alkyl chain (chain) having 1-6 carbon atoms, more p�edocfile, having 1-4 carbon atoms, halogen atom, halogenated alkyl group (preferably having an alkyl chain having 1-4 carbon atoms), hydroxy - group and amino group.

With respect to the group represented by R3concrete examples can preferably be described, for example, using peredelnoj group, methylpyridyl group, ethylpyridine group, propylpyridine group, methoxypyridine group, ethoxypyridine group, propylhexedrine group, hydroxypyridine group, aminopyridine group, n-methylaminopropyl group, n-ethylenepropylene group, N,N,-dimethylaminopyridine group, N,N,-diethylaminophenyl group, chloropyridine group, forberedelse group, diferencijalno group, triftormetilfullerenov group, phenyl group, methylphenylene group, ethylenimine group, propylaniline group, methoxyphenyl group, ethoxyphenyl group, propylhexedrine group, hydroxyproline group, aminoaniline group, n-methylaminophenol group, n-acylaminopenicillins group, N,N,-dimethylaminophenyl group, N,N-diethylaminophenyl group, chloraniline group, fluorophenyl group, defterlerini group, triftormetilfullerenov group, naftilos group, methylnaphthalenes group, ethylnaphthalene group, propyl�attirney group, methoxynaphthalene group, ethoxyethylene group, propylhexedrine group, hydroxynaphthyl group, aminonaphthalene group, n-methylaminomethyl group, n-ethylaminomethyl group, N,N-dimethylaminomethylene group, N,N-diethylaminomethyl group, chloronaphthalenes group, tomatillos group, definateley group, triftormetilfullerenov group, biphenyl group, methylpiperidino group, ethylbiphenyl group, methoxybiphenyl group and ethoxymethylene group. More preferably, it is possible to appropriately illustrate peredelnoj group, phenyl group, methylphenylene group, ethylenimine group, methoxyphenyl group, ethoxyphenyl group, fluorophenyl group, triftormetilfullerenov group, naftalina group and biphenyl group.

The number of substituents on an aromatic group, a condensed polycyclic aromatic group or heterocyclic group may preferably be illustrated as 0-3, and more preferably, this amount is 0 or 1. One or more substituents as described above, can exist independently, respectively, as a Deputy (deputies) for the aliphatic hydrocarbon group, an aromatic group, a condensed polycyclic aromatic group �on the heterocyclic group.

As described above, n is an integer equal to 1 or 2 and m is an integer from 0 to 3.

The connections defined in <2>, described above, which are not included in the connections defined in <3> or <4>, described above, are illustrated specifically. They can preferably be illustrated n-(phenylethylamine)cysteine acid, n-(phenylpropylamine)cysteine acid, n-(benzylcarbamoyl)cysteine acid, n-(methylbenzyloxycarbonyl)cysteine acid, n-(ethylbenzylamine)cysteine acid, n-(propylenecarbonate)cysteine acid, n-(butylbenzylamine)cysteine acid, n-(methoxybenzylidene)cysteine acid, n-(ethoxybenzylidene)cysteine acid, n-(propylacetophenone)cysteine acid, n-(butyloxycarbonyl)cysteine acid, n-(hydroxybenzylidene)cysteine acid, n-(aminobenzylidene)cysteine acid, n-(N'-methylaminoanthraquinone)cysteine acid, n-(N'-ethylaminoethanol)cysteine acid, n-(N',N'-dimethylaminobenzylidene)cysteine acid, n-(N',N'-diethylaminoethylamine)cysteine acid, n-(chlorobenzylidene)cysteine acid, n-(forbindelserne)cysteine acid, n-(diferenzierbarer)cysteine acid, n-(triftormetilfullerenov)cysts�inovas acid, complex ethyl ester of n-(phenylethylamine)cysteine acid, complex ethyl ester of n-(phenylpropylamine)cysteine acid, complex ethyl ester [N-(benzylcarbamoyl)cysteine acid], complex ethyl ester [N-(methylbenzyloxycarbonyl)cysteine acid], complex ethyl ester [N-(ethylbenzylamine)cysteine acid], complex ethyl ester [N-(propylenecarbonate)cysteine acid], complex ethyl ester [N-(butylbenzylamine)cysteine acid], complex ethyl ester [N-(methoxybenzylidene)cysteine acid], complex ethyl ester [N-(ethoxybenzylidene)cysteine acid], complex ethyl ester [N-(propylacetophenone)cysteine acid], complex ethyl ester [N-(butyloxycarbonyl)cysteine acid], complex ethyl ester [N-(hydroxybenzylidene)cysteine acid], complex ethyl ester [N-(aminobenzylidene)cysteine acid], complex ethyl ester [N-(N'-methylaminoanthraquinone)cysteine acid], complex ethyl ester [N-(N'-ethylaminoethanol)cysteine acid], complex ethyl ester [N-(N',N'-dimethylaminobenzylidene)cysteine acid], complex ethyl ester [N-(N',N'-diethylaminoethylamine)cysteine acid], complex ethyl ester [N-(chlorobenzylidene)cysteine acid], complex floor�charger ether [N-(forbindelserne)cysteine acid], complex ethyl ester [N-(diferenzierbarer)cysteine acid], complex ethyl ester [N-(triftormetilfullerenov)cysteine acid], n-(phenylethylamine)homocysteinemia acid, n-(phenylpropylamine)homocysteinemia acid, n-(benzylcarbamoyl)homocysteinemia acid, n-(methylbenzyloxycarbonyl)homocysteinemia acid, n-(ethylbenzylamine)homocysteinemia acid, n-(propylenecarbonate)homocysteinemia acid, n-(butylbenzylamine)homocysteinemia acid, n-(methoxybenzylidene)homocysteinemia acid, n-(ethoxybenzylidene)homocysteinemia acid, n-(propylacetophenone)homocysteinemia acid, n-(butyloxycarbonyl)homocysteinemia acid, n-(hydroxybenzylidene)homocysteinemia acid, n-(aminobenzylidene)homocysteinemia acid, n-(N'-methylaminoanthraquinone)homocysteinemia acid, n-(N'-ethylaminoethanol)homocysteinemia acid, n-(N',N'-dimethylaminobenzylidene)homocysteinemia acid, n-(N',N'-diethylaminoethylamine)homocysteinemia acid, n-(chlorobenzylidene)homocysteinemia acid, n-(forbindelserne)homocysteinemia acid, n-(diferenzierbarer)homocysteinemia acid, n-(triftormetilfullerenov)homocysteinemia acid, complex ethyl ester of n-(phenylethylamine)homocysteine�howling acid, complex ethyl ester of n-(phenylpropylamine)homocysteinemia acid, complex ethyl ester [N-(benzylcarbamoyl)homocysteinemia acid], complex ethyl ester [N-(methylbenzyloxycarbonyl)homocysteinemia acid], complex ethyl ester [N-(ethylbenzylamine)homocysteinemia acid], complex ethyl ester [N-(propylenecarbonate)homocysteinemia acid], complex ethyl ester [N-(butylbenzylamine)homocysteinemia acid], complex ethyl ester [N-(methoxybenzylidene)homocysteinemia acid], complex ethyl ester [N-(ethoxybenzylidene)homocysteinemia acid], complex ethyl ester [N-(propylacetophenone)homocysteinemia acid], complex ethyl ester [N-(butyloxycarbonyl)homocysteinemia acid], complex ethyl ester [N-(hydroxybenzylidene)homocysteinemia acid], complex ethyl ester [N-(aminobenzylidene)homocysteinemia acid], complex ethyl ester [N-(N'-methylaminoanthraquinone)homocysteinemia acid], complex ethyl ester [N-(N'-ethylaminoethanol)homocysteinemia acid], complex ethyl ester [N-(N',N'-dimethylaminobenzylidene)homocysteinemia acid], complex ethyl ester [N-(N',N'-diethylaminoethylamine)homocysteinemia acid], complex ethyl ester [N-(chlorobenzylidene)homocysteinemia acid], CL�l ethyl ether [N-(forbindelserne)homocysteinemia acid], complex ethyl ester [N-(diferenzierbarer)homocysteinemia acid], complex ethyl ester [N-(triftormetilfullerenov)homocysteinemia acid], their isomers and/or their pharmacologically acceptable salts.

Compounds as described above have an excellent effect of preventing or reducing the pigmentation. In addition, the compounds are excellent in the solubility in hydrophilic or lipophilic solvent, and is simple obtaining a pharmaceutical product, such as the preparation for external use on the skin or something like that. In addition, the compounds are excellent in retention in the skin and stability of the drug, and compounds show excellent effects of prevention or reduction of pigmentation.

Now will be described the connection defined in <3> described above. In the formula, R1represents a hydrogen atom or alkyl group with a linear or branched chain having 1-8 carbon atoms; R2represents a hydrogen atom; R3is a substituted or unsubstituted aromatic group, a substituted or unsubstituted condensed polycyclic aromatic group or a substituted or unsubstituted heterocyclic group having 5-15 carbon atoms; n represents an integer num�, is 1 or 2, and m represents 0.

R1as described above, represents a hydrogen atom or alkyl group with a linear or branched chain having 1-8 carbon atoms, more preferably having 1-4 carbon atoms. Specific examples can preferably be illustrated, for example, hydrogen atom, methyl group, ethyl group, propyl group, butyl group, Pintilei group, hexylene group, heptylene group and aktiline group. More preferably, it can be suitably illustrated by a hydrogen atom, a methyl group and an ethyl group.

R3as described above, represents a substituted or unsubstituted aromatic group, a substituted or unsubstituted condensed polycyclic aromatic group or a substituted or unsubstituted heterocyclic group having 5 to 15 carbon atoms. In regard to the Deputy, it can preferably be illustrated, for example, an alkyl group having 1-6 carbon atoms, more preferably having 1-4 carbon atoms, alkoxy group having an alkyl chain having 1-6 carbon atoms, more preferably having 1-4 carbon atoms, alkylamino having alkyl chain (chain) having 1-6 carbon atoms, more preferably having 1 to 4 atom angle�ode, a halogen atom, halogenated alkyl group (preferably having an alkyl chain having 1-4 carbon atoms), hydroxy group and amino group.

With respect to the group represented by R3concrete examples can preferably be illustrated, for example, using peredelnoj group, methylpyridyl group, ethylpyridine group, propylpyridine group, methoxypyridine group, ethoxypyridine group, propylhexedrine group, hydroxypyridine group, aminopyridine group, n-methylaminopropyl group, n-ethylenepropylene group, N,N,-dimethylaminopyridine group, N,N,-diethylaminophenyl group, chloropyridine group, forberedelse group, diferencijalno group, triftormetilfullerenov group, phenyl group, methylphenylene group, ethylenimine group, propylaniline group, methoxyphenyl group, ethoxyphenyl group, propylhexedrine group, hydroxyproline group, aminoaniline group, n-methylaminophenol group, n-acylaminopenicillins group, N,N,-dimethylaminophenyl group, N,N-diethylaminophenyl group, chloraniline group, fluorophenyl group, defterlerini group, triftormetilfullerenov group, naftilos group, methylnaphthalenes group, ethylnaphthalene group, propylheptyl group, IU�oxymatrine group, ethoxynaphthalene group, propylhexedrine group, hydroxynaphthyl group, aminonaphthalene group, n-methylaminomethyl group, n-ethylaminomethyl group, N,N-dimethylaminomethylene group, N,N-diethylaminomethyl group, chloronaphthalenes group, tomatillos group, definateley group, triftormetilfullerenov group, biphenyl group, methylpiperidino group, ethylbiphenyl group, methoxybiphenyl group and ethoxymethylene group. More preferably, it is possible to appropriately illustrate peredelnoj group, phenyl group, methylphenylene group, ethylenimine group, methoxyphenyl group, ethoxyphenyl group, fluorophenyl group, triftormetilfullerenov group, naftalina group and biphenyl group.

The number of substituents on an aromatic group, a condensed polycyclic aromatic group or heterocyclic group may preferably be illustrated as 0-3, and more preferably, this amount is 0 or 1. One or more substituents as described above, can exist independently, respectively, as a Deputy (deputies) for the aliphatic hydrocarbon group, an aromatic group, a condensed polycyclic aromatic group or heterocyclic�certification group.

As described above, n is an integer equal to 1 or 2 and m represents 0.

The connections defined in <3>, described above, which are not included in the connections defined in <4>, described above, are illustrated specifically. They can preferably be illustrated n-(benzoyl)homocysteinemia acid, n-(p-toluoyl)homocysteinemia acid (Compound 6), n-(ethylbenzoyl)homocysteinemia acid, n-(propylbenzoyl)homocysteinemia acid, n-(butylbenzoyl)homocysteinemia acid, n-(methoxybenzoyl)homocysteinemia acid, n-(ethoxybenzoyl)homocysteinemia acid, n-(propylacetate)homocysteinemia acid, n-(butyloxycarbonyl)homocysteinemia acid, n-(hydroxybenzoyl)homocysteinemia acid, n-(aminobenzoyl)homocysteinemia acid, n-(N'-methylaminomethyl)homocysteinemia acid, n-(N'-ethylaminomethyl)homocysteinemia acid, n-(N',N'-dimethylaminobenzoyl)homocysteinemia acid, n-(N',N'-diethylaminobenzoic)homocysteinemia acid, n-(chlorobenzoyl)homocysteinemia acid, n-(fluorobenzoyl)homocysteinemia acid, n-(differentail)homocysteinemia acid, n-(trifloromethyl)homocysteinemia acid, complex ethyl ester [N-(benzoyl)homocysteinemia acid], complex ethyl ester [N-(toluoyl)homocysteinemia acid], complex ethyl ester [N-(FL�benzoyl)homocysteinemia acid], complex ethyl ester [N-(propylbenzoyl)homocysteinemia acid], complex ethyl ester [N-(butylbenzoyl)homocysteinemia acid], complex ethyl ester [N-(methoxybenzoyl)homocysteinemia acid], complex ethyl ester [N-(ethoxybenzoyl)homocysteinemia acid], complex ethyl ester [N-(propylacetate)homocysteinemia acid], complex ethyl ester [N-(butyloxycarbonyl)homocysteinemia acid], complex ethyl ester [N-(hydroxybenzoyl)homocysteinemia acid], complex ethyl ester [N-(aminobenzoyl)homocysteinemia acid], complex ethyl ester [N-(N'-methylaminomethyl)homocysteinemia acid], complex ethyl ester [N-(N'-ethylaminomethyl)homocysteinemia acid], complex ethyl ester [N-(N',N'-dimethylaminobenzoyl)homocysteinemia acid], complex ethyl ester [N-(N',N'-diethylaminobenzoic)homocysteinemia acid], complex ethyl ester [N-(chlorobenzoyl)homocysteinemia acid], complex ethyl ester [N-(fluorobenzoyl)homocysteinemia acid], complex ethyl ester [N-(differentail)homocysteinemia acid], complex ethyl ester [N-(trifloromethyl)homocysteinemia acid], n-(naphtol)homocysteinemia acid, n-(mutilator)homocysteinemia acid, n-(aternator)homocysteinemia acid, n-(propylheptyl)homocysteinemia acid, n-(mutilator)Gomez�Steinway acid, n-(methoxymethyl)homocysteinemia acid, n-(ethoxymethyl)homocysteinemia acid, n-(propylacetate)homocysteinemia acid, n-(butylacetate) homocysteinemia acid, n-(hydroxynaphthyl) homocysteinemia acid, n-(aminocaproyl)homocysteinemia acid, n-(N'-methylaminomethyl)homocysteinemia acid, n-(N'-ethylaminomethyl)homocysteinemia acid, n-(N',N'-dimethylaminoethyl)homocysteinemia acid, n-(N',N'-diethylaminoethyl)homocysteinemia acid, n-(chloronaphthyl)homocysteinemia acid, n-(tornator)homocysteinemia acid, n-(deformatter)homocysteinemia acid, n-(triptoreline)homocysteinemia acid, complex ethyl ester [N-(naphtol)homocysteinemia acid], complex ethyl ester [N-(mutilator)homocysteinemia acid], complex ethyl ester [N-(aternator)homocysteinemia acid], complex ethyl ester [N-(propylheptyl)homocysteinemia acid], complex ethyl ester [N-(mutilator)homocysteinemia acid], complex ethyl ester [N-(methoxyethyl)homocysteinemia acid], complex ethyl ester [N-(ethoxymethyl)homocysteinemia acid], complex ethyl ester [N-(propylacetate)homocysteinemia acid], complex ethyl ester [N-(butylacetate) homocysteinemia acid], complex ethyl ester [N-(hydroxynaphthyl) d�acid cysteine], complex ethyl ester [N-(aminocaproyl)homocysteinemia acid], complex ethyl ester [N-(N'-methylaminomethyl)homocysteinemia acid], complex ethyl ester [N-(N'-ethylaminomethyl)homocysteinemia acid], complex ethyl ester [N-(N',N'-dimethylaminoethyl)homocysteinemia acid], complex ethyl ester [N-(N',N'-diethylaminoethyl)homocysteinemia acid], complex ethyl ester [N-(chloronaphthyl)homocysteinemia acid], complex ethyl ester [N-(tornator)homocysteinemia acid], complex ethyl ester [N-(deformatter)homocysteinemia acid], complex ethyl ester [N-(triptoreline)homocysteinemia acid], n-(biphenylcarboxylic)homocysteinemia acid, n-(metilbutilovy)homocysteinemia acid, n-(ethylmethylketone)homocysteinemia acid, n-(propylpiperonyl)homocysteinemia acid, n-(butalbital.carbons)homocysteinemia acid, n-(methoxyphenylacetyl)homocysteinemia acid, n-(ethoxymethylene)homocysteinemia acid, n-(propylacetophenone) homocysteinemia acid, n-(butyloxycarbonyl)homocysteinemia acid, n-(hydroxyphenylethyl)homocysteinemia acid, n-(aminopiperidine)homocysteinemia acid, n-(N'-methylaminoethylcarbonyl)homocysteinemia acid, n-(N'-ethylaminomethyl)Gomez�Steinway acid, n-(N',N'-dimethylaminomethylene)homocysteinemia acid, n-(N',N'-diethylaminoethylamine)homocysteinemia acid, n-(chlorophenylsulfonyl)homocysteinemia acid, n-(forbidenready)homocysteinemia acid, n-(diversifizieren)homocysteinemia acid, n-(triftormetilfullerenov)homocysteinemia acid, complex ethyl ester [N-(biphenylcarboxylic)homocysteinemia acid], complex ethyl ester [N-(metilbutilovy)homocysteinemia acid], complex ethyl ester [N-(ethylmethylketone)homocysteinemia acid], complex ethyl ester [N-(propylpiperonyl)homocysteinemia acid], complex ethyl ester [N-(butalbital.carbons)homocysteinemia acid], complex ethyl ester [N-(methoxyphenylacetyl)homocysteinemia acid], complex ethyl ester [N-(ethoxymethylene)homocysteinemia acid], complex ethyl ester [N-(propylacetophenone) homocysteinemia acid], complex ethyl ester [N-(butyloxycarbonyl)homocysteinemia acid], complex ethyl ester [N-(hydroxyphenylethyl)homocysteinemia acid], complex ethyl ester [N-(aminopiperidine)homocysteinemia acid], complex ethyl ester [N-(N'-methylaminoethylcarbonyl)homocysteinemia acid], complex ethyl ester [N-(N'-ethylaminoethanol�yl)homocysteinemia acid], complex ethyl ester [N-(N',N'-dimethylaminomethylene)homocysteinemia acid], complex ethyl ester [N-(N',N'-diethylaminoethylamine)homocysteinemia acid], complex ethyl ester [N-(chlorophenylsulfonyl)homocysteinemia acid], complex ethyl ester [N-(forbidenready)homocysteinemia acid], complex ethyl ester [N-(diversifizieren)homocysteinemia acid], complex ethyl ester [N-(triftormetilfullerenov)homocysteinemia acid], their isomers and/or their pharmacologically acceptable salts. More preferably, it is possible to appropriately illustrate n-(o-toluoyl)homocysteinemia acid, n-(m-toluoyl)homocysteinemia acid, n-(p-toluoyl)homocysteinemia acid (Compound 6), their isomers and/or their pharmacologically acceptable salts.

Compounds as described above have an excellent effect of preventing or reducing the pigmentation. In addition, the compounds are excellent in the solubility in hydrophilic or lipophilic solvent, and is simple obtaining a pharmaceutical product, suchas a preparation for external use on the skin or something like that. In addition, the compounds are excellent in retention on the skin and on the stability of the drug, and compounds show excellent air�istie prevent or reduce pigmentation.

Now will be described the connection defined in <4> described above. In the formula, R1represents a hydrogen atom or alkyl group with a linear or branched chain having 1-8 carbon atoms; R2represents a hydrogen atom; R3is a substituted or unsubstituted aromatic group, a substituted or unsubstituted condensed polycyclic aromatic group or a substituted or unsubstituted heterocyclic group having 5-15 carbon atoms; n represents 1; and m represents 0.

R1as described above, represents a hydrogen atom or alkyl group with a linear or branched chain having 1-8 carbon atoms, more preferably having 1-4 carbon atoms. Specific examples can preferably be illustrated, for example, hydrogen atom, methyl group, ethyl group, propyl group, butyl group, Pintilei group, hexylene group, heptylene group and aktiline group. More preferably, it is possible to appropriately illustrate a hydrogen atom, methyl group and ethyl group.

R3as described above, represents a substituted or unsubstituted aromatic group, a substituted or unsubstituted condensed polycyclic aromatic gr�foam or substituted or unsubstituted heterocyclic group, having 5-15 carbon atoms. In regard to the Deputy, it can preferably be illustrated, for example, an alkyl group having 1-6 carbon atoms, more preferably having 1-4 carbon atoms, alkoxy group having an alkyl chain having 1-6 carbon atoms, more preferably having 1-4 carbon atoms, alkylamino having alkyl chain (chain) having 1-6 carbon atoms, more preferably having 1-4 carbon atoms, halogen atom, halogenated alkyl group (preferably having an alkyl chain having 1-4 carbon atoms), hydroxy-group and amino group.

With respect to the group represented by R3specific examples preferably may be illustrated, for example, using peredelnoj group, methylpyridyl group, ethylpyridine group, propylpyridine group, methoxypyridine group, ethoxypyridine group, propylhexedrine group, hydroxypyridine group, aminopyridine group, n-methylaminopropyl group, n-ethylenepropylene group, N,N,-dimethylaminopyridine group, N,N,-diethylaminophenyl group, chloropyridine group, forberedelse group, diferencijalno group, triftormetilfullerenov group, phenyl group, methylphenylene group, ethylenimine group, propylaniline g�uppy, methoxyphenyl group, ethoxyphenyl group, propylhexedrine group, hydroxyproline group, aminoaniline group, n-methylaminophenol group, n-acylaminopenicillins group, N,N,-dimethylaminophenyl group, N,N-diethylaminophenyl group, chloraniline group, fluorophenyl group, defterlerini group, triftormetilfullerenov group, naftilos group, methylnaphthalenes group, ethylnaphthalene group, propylheptyl group, methoxynaphthalene group, ethoxyethylene group, propylhexedrine group, hydroxynaphthyl group, aminonaphthalene group, n-methylaminomethyl group, n-ethylaminomethyl group, N,N-dimethylaminomethylene group, N,N-diethylaminomethyl group, chloronaphthalenes group, tomatillos group, definateley group, triftormetilfullerenov group, biphenyl group, methylpiperidino group, ethylbiphenyl group, methoxybiphenyl group and ethoxymethylene group. More preferably, it can preferably be illustrated peredelnoj group, phenyl group, methylphenylene group, ethylenimine group, methoxyphenyl group, ethoxyphenyl group, fluorophenyl group, triftormetilfullerenov group, naftalina group and biphenyl group.

The number of substituents on the aromatic group, gender�condensed cyclic aromatic group or heterocyclic group may preferably be illustrated as 0-3, and more preferably, this amount is 0 or 1. One or more substituents as described above, can exist independently, respectively, as a Deputy (deputies) for the aliphatic hydrocarbon group, an aromatic group, a condensed polycyclic aromatic group or heterocyclic group

As described above, n represents 1 and m represents 0.

Specific examples are illustrated in relation to compounds defined in <4> described above. They can preferably be illustrated n-(pyridylcarbonyl)cysteine acid, n-(methylphenylcarbinol)cysteine acid, n-(Ethylenediamine)cysteine acid, n-(propylenecarbonate)cysteine acid, n-(methoxypyridine)cysteine acid, n-(ethoxypyridine)cysteine acid, n-(propylhexedrine)cysteine acid, n-(hydroxypyridinone)cysteine acid, n-(aminopenicillanic)cysteine acid, n-(N'-methylaminopropane)cysteine acid, n-(N'-acylaminoalkyl)cysteine acid, n-(N',N'-dimethylaminopyridine)cysteine acid, n-(N',N'-diethylaminopropylamine)cysteine acid, n-(chloropyridinyl)cysteine acid, n-(forberedelserne)cysteine acid, n-(�triftormetilfullerenov)cysteine acid, n-(benzoyl)cysteine acid, n-(o-toluoyl)cysteine acid (Compound 1), n-(m-toluoyl)cysteine acid (Compound 2), n-(p-toluoyl)cysteine acid (Compound 3), n-(ethylbenzoyl)cysteine acid, n-(propylbenzoyl)cysteine acid, n-(butylbenzoyl)cysteine acid, n-(o-methoxybenzoyl)cysteine acid, n-(m-methoxybenzoyl)cysteine acid, n-(p-methoxybenzoyl)cysteine acid (Compound 4), n-(ethoxybenzoyl)cysteine acid, n-(propylacetate)cysteine acid, n-(butyloxycarbonyl)cysteine acid, n-(hydroxybenzoyl)cysteine acid, n-(aminobenzoyl)cysteine acid, n-(N'-methylaminomethyl)cysteine acid, n-(N'-ethylaminomethyl)cysteine acid, n-(N',N'-dimethylaminobenzoyl)cysteine acid, n-(N',N'-diethylaminobenzoic)cysteine acid, n-(chlorobenzoyl)cysteine acid, n-(fluorobenzoyl)cysteine acid, n-(differentail)cysteine acid, n-(trifloromethyl)cysteine acid, n-(naphtol)cysteine acid, n-(mutilator)cysteine acid, n-(aternator)cysteine acid, n-(propylheptyl)cysteine acid, n-(mutilator)cysteine acid, n-(methoxymethyl)cysteine acid, n-(ethoxymethyl)cysteine acid, n-(propylacetate)cysteine acid, n-(butylacetoacetate acid, n-(hydroxynaphthyl)cysteine acid, n-(aminocaproyl)cysteine acid, n-(N'-methylaminomethyl)cysteine acid, n-(N'-ethylaminomethyl)cysteine acid, n-(N',N'-dimethylaminoethyl)cysteine acid, n-(N',N'-diethylaminoethyl)cysteine acid, n-(chloronaphthyl)cysteine acid, n-(tornator)cysteine acid, n-(deformatter)cysteine acid, n-(triptoreline)cysteine acid, n-(biphenylcarboxylic)cysteine acid (Compound 5), n-(metilbutilovy)cysteine acid, n-(ethylmethylketone)cysteine acid, n-(propylpiperonyl)cysteine acid, n-(butalbital.carbons)cysteine acid, n-(methoxyphenylacetyl)cysteine acid, n-(ethoxymethylene)cysteine acid, n-(propylacetophenone)cysteine acid, n-(butyloxycarbonyl)cysteine acid, n-(hydroxyphenylethyl)cysteine acid, n-(aminopiperidine)cysteine acid, n-(N'-methylaminoethylcarbonyl)cysteine acid, n-(N'-ethylaminomethyl)cysteine acid, n-(N',N'-dimethylaminomethylene)cysteine acid, n-(N',N'-diethylaminoethylamine)cysteine acid, n-(chlorophenylsulfonyl)cysteine acid, n-(forbidenready)cysteine acid, n-(diversifizieren)cysts�inovas acid, n-(triftormetilfullerenov)cysteine acid, their isomers and/or their pharmacologically acceptable salts. More preferably, they can be suitably illustrate n-(o-toluoyl)cysteine acid (Compound 1), n-(m-toluoyl)cysteine acid (Compound 2), n-(p-toluoyl)cysteine acid (Compound 3), n-(o-methoxybenzoyl)cysteine acid, n-(m-methoxybenzoyl)cysteine acid, n-(p-methoxybenzoyl)cysteine acid (Compound 4), n-(2-phenylbenzyl)cysteine acid, n-(3-phenylbenzyl)cysteine acid and n-(4-phenylbenzyl)cysteine acid (Compound 5).

Connection, as described above, have an excellent preventative effect or impact of a reduction of pigmentation. In addition, the compounds are excellent in the solubility in hydrophilic or lipophilic solvent, and is simple obtaining a pharmaceutical product, such as the preparation for external use on the skin or something like that. In addition, the compounds are excellent in retention in the skin and stability of the drug, and compounds show excellent effects of prevention or reduction of pigmentation.

In regard to the connection, as described above, is it possible to use their isomers. Isomer represents, for example, �stereoisomer, which is, for example, optical isomer. In addition, in respect of each connection represented by the General formula (1) described above, and the compounds defined in <2>-<4>, there are optical isomers, D-isomer and L-isomer, in addition to the racemic compound (DL-isomer). Any of these isomers demonstrate excellent exposure to prevent or reduce pigmentation. However, the L-isomer can preferably be illustrated from the viewpoint of, for example, security for the living organism and stability in pharmaceutical drug.

The connection represented by the General formula (1) described above, the compounds defined in <2>-<4>, their isomers and/or their pharmacologically acceptable salts can also be obtained starting from the commercially available acid cysteine, homocysteine acid and/or their derivatives via reactions of deprotection, of binding and protection in accordance with the following further method of obtaining described in the present description, or in the usual way, described in “Fundamental and Experiments for Peptide Synthesis(MARUZEN), et al.

Connection, as described above, can also be used as is, as an agent for the prevention or reduction of pigmentation. In addition, they can also be used in the form of salts after converting them in the form of a salt by R�Ki their pharmacologically acceptable acid or base. They can preferably be illustrated, for example, salts of mineral acids, including, for example, hydrochloride, sulfate, nitrate, phosphate and carbonate; salts of organic acids, including, for example, maleate, fumarate, oxalate, citrate, lactate, tartrate, methanesulfonate, para-toluensulfonate and benzolsulfonat; salts of alkaline metals such as sodium salt and potassium salt; salts of alkaline earth metals such as calcium salt and magnesium salt; salts of organic amines, including, for example, a salt of triethylamine, triethanolamine salt, ammonium salt, salt of monoethanolamine and a salt of piperidine; and salts of basic amino acids, such as lysine salt and the salt of alginic acid.

The connection represented by the General formula (1), the connections defined in <2>-<4>, their isomers and/or their pharmacologically acceptable salts, which are obtained thus, as described above, have an excellent preventative effect or reduction of pigmentation. For this reason, they may be suitable for use as active ingredients in preparations for external use on the skin. With regard to pharmacological effects of the active ingredient, as described above, according to estimates, preventive or debilitating activity is caused by suppressing the production of melanin through�Twomey inhibit the activity of activated melanocytes, for example, the activity of inhibiting the activity of tyrosinase, such as the activity of inhibition of the tyrosinase enzyme, the activity of suppressing the expression of the tyrosinase gene, the activity of suppressing the expression of tyrosinase protein and activity of degradation of tyrosinase-related protein.

As shown in the case study Examples described hereinafter, the compounds represented by the General formula (1) described above, the compounds defined in <2>-<4> described above, their isomers and/or their pharmacologically acceptable salts, as confirmed, have excellent effects of inhibiting the activation of melanocytes in the evaluation system in vitro. It is considered that the compound represented by the General formula (1) described above, the compounds defined in <2>-<4> described above, their isomers and/or their pharmacologically acceptable salts exhibit confirmed the effects of suppressing pigmentation in the evaluation system in vivo by suppressing the production of melanin on the basis of, for example, the action of suppressing the activation of melanocyte as described above. That is, the compound represented by the General formula (1) described above, the compounds defined in <2>-<4> described above, their isomers and/or their pharmacologically acceptable salts are suitable for use as an active ingredient of an agent for the prevention or reduction�of pigmentation.

Any connection that provides any impact, other than preventive or debilitating effect on the pigmentation is also present in the compound represented by the General formula (1) described above, the compounds defined in <2>-<4>, their isomers and/or their pharmacologically acceptable salts. Any preparation for external use on the skin, which contains the connection for the impacts, as described above, is also within the technical scope of the present invention, because the effect of the present invention, provided that the main purpose is to obtain preventive or debilitating effects on pigmentation as impact compounds represented by the General formula (1) described above, the compounds defined in <2>-<4>, their isomers and/or their pharmacologically acceptable salts. Provides preparation for external use on skin of the present invention to prevent or reduce pigmentation. The purpose of "prevent or minimize pigmentation also includes a purpose that is consistent with any policy objectives, which are expected to be achieved through the prevention or reduction of pigmentation, for example, a goal of "whitening of the skin and reduce pigment spots.

<Preparation for naru�tion application to the skin according to the present invention>

The preparation for external use on skin of the present invention is characterized in that the preparation for external use on the skin contains an agent for the prevention or reduction of pigmentation, containing any of compounds represented by the General formula (1) described above, the compounds defined in <2>-<4>, their isomers and/or their pharmacologically acceptable salts.

To effectively demonstrate the preventive effect or reducing the pigmentation of the compounds represented by the General formula (1), compounds defined in <2>-<4>, their isomers and/or their pharmacologically acceptable salts, is preferred for the presence of one or more substances selected from the compounds represented by the General formula (1), compounds defined in <2>-<4>, their isomers and/or their pharmacologically acceptable salts, in a total quantity from 0.001% wt. up to 20 wt.%, more preferably, from 0.01 wt%. up to 10% wt., and even more preferably from 0.05 to 5 wt%. in relation to the total amount of the preparation for external use on the skin. If the content relative to the total amount of the preparation for external use on the skin less than 0.001 wt.%, preventive or debilitating effect on the pigmentation decreases. On the other hand, even when the amount greater than 20% �ACC., the effect reaches a plateau. For this reason, it is preferable to tailor the content described above in relation to the total amount of the preparation for external use on the skin.

In the preparation for external use on skin of the present invention, it is possible the presence of a random component, typically used for cosmetic preparation, other than main components as described above. With regard to an arbitrary component, as described above, may be present, for example, hydrocarbons including, for example, squalane, vaseline and microcrystalline wax; esters, such as jojoba oil, Carnauba wax and octyldodecanol; triglycerides, such as olive oil, beef tallow and coconut oil; fatty acids, such as stearic acid, oleic acid, and retinoic acid; higher alcohols including, for example, alerby alcohol, stearyl alcohol and octyldodecanol; anionic surfactants, including, for example, ester sultanhani acid and sodium polyoxyethyleneglycol; amphoteric surfactants, including, for example, alkylbetaine; cationic surfactants, including, for example, dialkylammonium; nonionic surfactants, including, for example, a complex sorbitol�new fatty acid ester, monoglyceride fatty acids and their adducts with polyoxyethylene, simple alkyl ether of polyoxyethylene and an ester of fatty acid and polyoxyethylene; polyhydric alcohols, including, for example, polyethylene glycol, glycerol and 1,3-butanediol; thickening/gelling agents; antioxidants; agents that absorb ultraviolet radiation; coloring materials; antiseptics and powders. The preparation for external use on skin of the present invention can be obtained without any difficulty by processing components, as described above, in accordance with a customary method, in addition to the agent for the prevention or reduction of pigmentation of the present invention.

The preparation for external use on skin of the present invention can be obtained by processing the main components and arbitrary components, as described above, in accordance with a customary method, and processing components, for example, in the form of lotion, face lotion, essence, cream, compacted cosmetic preparation or preparation for washing. May be taken any form of drug for external use on the skin, provided that it can be applied on the skin. Because the active ingredient penetrates into the skin for impact, more preferred is the use of the forms p�of Ephrata for external use, which are comfortable for the skin, such as lotion, a milky lotion, cream, essence, and the like.

The present invention will be explained in more detail hereinafter illustrated by means of Examples. However, it is not necessary to say that the present invention is not limited to the Examples as described below.

EXAMPLES

<Example 1: Synthesis of L-isomer of compound 1>

N-(o-Toluoyl)-L-cysteine acid (L-isomer of compound 1)

In the evaporation flask, 100 ml, add 3 g (17.7 mmol) of L-cysteine acid (Tokyo Chemical Industry Co., Ltd.), the 18 ml tetrahydrofuran (Wako Pure Chemical Industries, Ltd.) and 18 ml of water, and then the flask was cooled in an ice bath. After sufficient cooling, was added potassium carbonate 4,40 g (of 31.6 mmol) (Wako Pure Chemical Industries, Ltd.). o-Toluoyl chloride or 3.28 g (Tokyo Chemical Industry Co., Ltd.) added gradually so that the temperature of the reaction mixture did not increase. After the addition, the ice bath removed and the reaction mixture was stirred at room temperature. Progress of the reaction was confirmed by thin-layer chromatography, and then the tetrahydrofuran is evaporated under reduced pressure. The obtained residue was washed with ethyl acetate, and then pH adjust, it does not exceed 2 using hydrochloric acid. The filtrate was concentrated, IR it was added water (20 ml). Precipitiously crystals were obtained by filtration, and the crystals washed with acetone. The filtered crystals were dried at 60°C to produce a Compound 1 having the structure described above, 0.78 g (2,72 mmol). Typical values are as follows.

1H-NMR (D2O): δ 2,31 (3H, s), 3,42 (2H, m), with 4.86 (1H, m), 7,24 (2H, m), 7,35 (2H, m).

FAB-MS (negative ion mode): M/z=286 ([M-H]-).

<Example 2: Synthesis of L-isomer of compound 2>

N-(m-Toluoyl)-L-cysteine acid (L-isomer of compound 2)

In the evaporation flask, 100 ml, add 3 g (17.7 mmol) of L-cysteine acid (Tokyo Chemical Industry Co., Ltd.), 18 ml of tetrahydrofuran (Wako Pure Chemical Industries, Ltd.) and 18 ml of water, and then the flask was cooled in an ice bath. After sufficient cooling, gradually add the potassium carbonate 4,40 g (of 31.6 mmol) (Wako Pure Chemical Industries, Ltd.) and m-toluoyl chloride 2,19 g (Tokyo Chemical Industry Co., Ltd.) so that the temperature of the reaction mixture did not increase. The reaction is performed for 1 hour in an ice bath, and then add the m-trouillard of 1.09 g (Tokyo Chemical Industry Co., Ltd.). After the addition, the ice bath removed and the reaction mixture was stirred at room temperature. Progress of the reaction was confirmed by thin-layer chromatography, and then the tetrahydrofuran is evaporated under reduced pressure. Received about�burial was washed with ethyl acetate, and then adjust pH to no higher than 2 using hydrochloric acid. The filtrate is concentrated, and thereto was added water (18 ml). After aging at 4°C, precipitiously crystals are separated by filtration. The resulting crystals are washed with acetone, followed by filtration. The filtered crystals were dried at 60°C to produce a Compound 2 having the structure described above, 1.65 g (5,74 mmol). Typical values are as follows.

1H-NMR (DMSO-d6): δ a 2.36 (3H, s), to 2.94 (2H, m) to 4.41 (1H, m), of 7.36 (2H, d), 7,58 (2H, t), is 8.84 (1H, d), and 12.5 (1H, Shir.C).

FAB-MS (negative ion mode): M/z=286 ([M-H]-).

<Example 3: Synthesis of L-isomer of compound 3>

N-(p-Toluoyl)-L-cysteine acid (L-isomer compound 3)

In the evaporation flask, 100 ml, placed 5 g (26.7 mmol) of L-cysteine acid monohydrate (Sigma-Aldrich Co.), 20 ml of 1,4-dioxane (Wako Pure Chemical Industries, Ltd.) and 10 ml of water, and then the flask was cooled in an ice bath. After sufficient cooling, gradually add 8h. aqueous sodium hydroxide solution of 10.7 ml, and n-toluoyl chloride 3,36 ml (Sigma-Aldrich Corporation), dropwise so that the temperature of the reaction mixture did not increase. After completion of adding dropwise, the ice bath removed and the reaction mixture was stirred at room Tempe�the atur. Progress of the reaction was confirmed by thin-layer chromatography, and then 1,4-dioxane was evaporated under reduced pressure. The obtained residue was washed with ethyl acetate, then pH adjust, it does not exceed 2 using hydrochloric acid. The resulting aqueous solution was dried by freeze-drying, and the target substance was extracted with methanol. The methanol is evaporated under reduced pressure, and then carry out crystallization, followed by filtration. The filtered crystals are dried to produce a Compound 3 having the structure described above, 5,79 g (20,2 mmol). Typical values are as follows.

1H-NMR (D2O): δ 2,32 (3H, s), of 3.46 (2H, m), 4,87 (1H, m), 7,25 (2H, d), of 7.64 (2H, d).

FAB-MS (negative ion mode): M/z=286 ([M-H]-), 308 ([M+Na-H]-).

<Example 4: Synthesis of L-isomer compound 4>

N-(p-Methoxybenzoyl)-L-cysteine acid (L-isomer compound 4)

In the evaporation flask, 100 ml, was placed 2 g (to 11.8 mmol) of L-cysteine acid (Tokyo Chemical Industry Co., Ltd.), 12 ml of tetrahydrofuran (Wako Pure Chemical Industries, Ltd.) and 12 ml of water, and then the flask was cooled in an ice bath. After sufficient cooling, gradually add the potassium carbonate 2.94 g (21,3 mmol) (Wako Pure Chemical Industries, Ltd.) and 4-methoxybenzoyl chloride a solution of 1.61 g (Tokyo Chemical Industry Co., Ltd.) so that the temperature�tour the reaction mixture is not increased. The reaction is performed for 1 hour in an ice bath, then add 4-methoxybenzophenone 0,81 g (Tokyo Chemical Industry Co., Ltd.). After the addition, the ice bath removed and the reaction mixture was stirred at room temperature. Progress of the reaction was confirmed by thin-layer chromatography, and then the tetrahydrofuran is evaporated under reduced pressure. The obtained residue was washed with ethyl acetate, and then pH adjust, it does not exceed 2 using hydrochloric acid. Precipitiously crystals are filtered off and washed with water. The filtrate was concentrated, and re-precipitiously crystals are filtered out. The resulting crystals were combined, then washed with acetone. The crystals was filtered and then the filtered crystals were dried at 60°C to produce a Compound 4 having the structure described above, 2,47 g (8,14 mmol). Typical values are as follows.

1H-NMR (D2O): δ 3.45 m (2H, m), 3,81 (3H, s), is 4.85 (1H, m), 7,00 (2H, d), 7,72 (2H, d).

FAB-MS (negative ion mode): M/z=302 ([M-H]-).

<Example 5: Synthesis of L-isomer of compounds 5>

(N-Biphenylcarboxylic)-L-cysteine acid (L-isomer compound 5)

In the evaporation flask, 100 ml, was placed 2 g (to 11.8 mmol) of L-cysteine acid (Tokyo Chemical Industry Co., Ltd.), 12 ml of tetrahydrofuran (Wako Pure Chemical Industries, Ltd.) and 12 ml of water, and then the flask was cooled in an ice bath. After sufficient cooling, gradually add the potassium carbonate 2.94 g (21,3 mmol) (Wako Pure Chemical Industries, Ltd.) and 4-phenylbenzophenone 2.05 g (Tokyo Chemical Industry Co., Ltd.) so that the temperature of the reaction mixture did not increase. The reaction is carried out for 1.5 hours in an ice bath, then add 4-phenylbenzyl chloride and 1.02 g (Tokyo Chemical Industry Co., Ltd.). After the addition the ice bath is removed, and the reaction mixture was stirred at room temperature. Progress of the reaction was confirmed by thin-layer chromatography, and then the tetrahydrofuran is evaporated under reduced pressure. The obtained residue was washed with ethyl acetate, and then pH adjust, it does not exceed 2 using hydrochloric acid. Precipitiously crystals filtered off and washed with water. The resulting crystals are washed with acetone, followed by filtration. The filtered crystals were dried at 60°C to produce a Compound 5 having the structure described above, 2,37 g (6,78 mmol). Typical values are as follows.

1H-NMR (DMSO-d6): δ 2,96 (2H, m), of 4.54 (1H, q), of 7.42 (1H, m), 7,51 (2H, m), 7,74 (2H, d), 7,80 (2H, d), 7,90 (2H, d), quick 8.94 (1H, d).

FAB-MS (negative ion mode): M/z=348 ([M-H]-).

<Example 6: Synthesis of compounds 6>

N-(p-Toluoyl)homocysteinaemia (Compound 6)

In the evaporation flask, 100 ml, was placed 2 g (10.9 mmol) of DL-homocysteinemia acid (Sigma-Aldrich Co.), 12 ml of tetrahydrofuran (Wako Pure Chemical Industries, Ltd.) and 12 ml of water, and then the flask was cooled in an ice bath. After sufficient cooling, was added potassium carbonate 2.71 g (19,6 mmol) (Wako Pure Chemical Industries, Ltd.). Gradually add p-trouillard of 1.49 g (Sigma-Aldrich Corporation) so that the temperature of the reaction mixture did not increase. The reaction is performed for 1 hour in an ice bath, and then added again p-trouillard of 0.76 g (Sigma-Aldrich Corporation). After the addition, the ice bath removed and the reaction mixture was stirred at room temperature. Progress of the reaction was confirmed by thin-layer chromatography, and then the tetrahydrofuran is evaporated under reduced pressure. The obtained residue was washed with ethyl acetate, and then pH adjust, it does not exceed 2 using hydrochloric acid. The solution was filtered and then the filtrate is concentrated and added methanol. Precipitiously crystals are separated through filtration, and then washed with water. The crystals was filtered, and the filtered crystals were dried at 60°C to produce a Compound 6 having the structure described above, 1.95 g (6,47 mmol). Typical values are as follows.

1H-NMR (DMSO-d6): δ 2,12 (2H, m), of 2.35 (3H, s), of 2.57 (2H, t), 4,37 (1H,m), 7,26 (2H, d), 7,79 (2H, d), 9,02 (1H, d).

FAB-MS (negative ion mode): M/z=300 ([M-H]-).

<Example study 1: study of the inhibition of cell activation induced by UV, using normal human melanocytes>

The inhibitory effects of compounds on the activation of melanocytes by activating factor produced and released from normal human keratinocytes by ultraviolet radiation B (UV B), evaluated through the use of an index of cell proliferation of normal human melanocytes.

Normal human keratinocytes (Kurabo Industries, Ltd.) sown on Wednesday Humedia-KG2 (Kurabo Industries, Ltd.) at concentrations of 10×104cells/well in 24-well plate. Then, the cells are cultured within 24 hours.

The compound was dissolved at a concentration of 100 mm in DMSO, which was diluted 1000 times environment Humedia-KG2 and is used as a solution for sample. As for the positive control group, tranexamic acid was dissolved at a concentration of 100 mm in DMSO, which was diluted 1000 times environment Humedia-KG2, as a solution for sample to positive control. With respect to the negative control group, DMSO was diluted 1000 times environment Humedia-KG2 as a solution for the negative control sample. The concentration of the compounds are selected so that they are not inhibited Strait�ferariu cells.

Environment normal human keratinocytes replace environment Humedia-KG2 (solution sample) containing the compound at a predetermined concentration, and the cells are cultured for an additional 24 hours. After that, the medium is replaced with PBS (phosphate saline buffer), and cells irradiated with ultraviolet B (UV B) at 5 MJ/cm2through the use of ultraviolet light (FL20S・E-30/DMR, Toshiba Medical Supply Co., Ltd.) as a light source. After ultraviolet irradiation, the PBS is replaced by a solution for sample. Cells are cultured for an additional 24 hours and then conditioned medium collected. Cells of normal human melanocytes seeded at a concentration of 3×104cells/well in 96-well plates using medium Medium 254 (Kurabo Industries, Ltd.). Cells are cultivated for 24 hours. Thereafter, the medium is replaced with conditioned medium collected from normal human keratinocytes, and cells are cultured for an additional 24 hours. After 24 hours, the medium is replaced by medium Humedia-KG2 containing 0.5 mg/ml 3-(4,5-dimethyl-2-thiazoyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), and cultured for 3 hours.

The amount of formazan is measured as the coefficient of absorption at 570 nm and 690 nm for cell lysate, lysed with 2-propanol, using a reader for microplates (Benchmark Plus, Bio-Rad) through�Twomey subtraction of absorbance at 690 nm from the absorption at 570 nm.

The inhibitory effect of each of compounds on the proliferation of melanocytes is calculated as the ratio (%) the production of formazan, when the absorption coefficient of the negative control group in which add the DMSO and carry out the irradiation In UV, is defined as 100%.

One can estimate that small respect, the production of formazan shows that the proliferation of melanocytes is low. For this reason, unrelated to the production of formazan indicates that the inhibitory effect of the compounds is strong, it is directed against the activation of melanocytes using factor activation of melanocytes released from keratinocytes.

Table 1
ConnectionUltravio-years B (UV-B)
(MJ/cm2)
The ratio of proliferation of melanocytes
Average value (%)Standard deviation (%)
DMSO048,1A 3.78
DMSO (negative control)5100, 7,08
Tranexamic acid (positive control)5For 80.98,76
L-Isomer of compound 1573,77,02
L-Isomer of compound 2577,0Of 5.72
L-Isomer of compound 3558,48,37

L-Isomer compound 4565,66,45
L-Isomer of compounds 5579,0To 10.38
Compound 6571,33,55
The ratio of proliferation of melanocytes shows the mean value ± S. D.(standard deviation) for 3 samples.

Table 1 shows that all these compounds have excellent inhibition tion�ornago impact although inhibitory effects of the compounds are different. For this reason, it is shown that all compounds have excellent inhibitory effect on the activation of melanocytes caused by activating factor produced and released from normal human keratinocytes.

<Example study 2: study of the inhibition of pigmentation caused by UV radiation, using Guinea pigs >

The hair on the skin of the back of each of the eight pigmented Guinea pigs removed and shaved using electric clippers animals and razors, and each of the sections are covered with black cloth, having a total of four (two top and bottom and two on the right and left) of the window for irradiation with dimensions 2×2 cm, and then irradiated with ultraviolet rays at 300 MJ/cm2using the lamp FL20S·E30 as a light source. The operation is repeated on days 1, 3, 5 and 8 after the start of the study to cause pigmentation on the four studied plots of Compound 3 is dissolved in ethanol at a concentration of 0.5% (wt./volume), to obtain samples for the application. In addition, as a control, ethanol, by itself, is used as a sample for the application. Day 1 of the study after irradiation with ultraviolet light, start applying samples. Appropriate samples applied in a number of�ve 30 μl once a day defined in the areas of research, and the application was continued for 6 weeks (until day 42 of the study). Whiteness (L* values) for each of the study plots was measured with a colorimeter (CR-200, Konica Minolta Holdings, Inc.) before irradiation with ultraviolet light on the first day of application (day 1) and after 6 weeks (on 43rd day of the study), and the value of ∆L* is calculated by subtracting the value of L* before irradiation with ultraviolet from the value of L* in 43rd day of the study. Table 2 shows the results when the level of pigmentation becomes stronger, the value of ∆L* becomes smaller. For this reason, we can estimate that when the value of ∆L* becomes larger (high numerical value), pigmentation was inhibited stronger. The results show that compound 3 is clearly inhibit pigmentation induced by ultraviolet radiation, at a concentration of 0.5%, when it is applied to the skin.

Table 2
The research sampleConcentrationthe value of ΔL*
The control group with the solvent-Down 10.7±0,78
Union 30,5%-8,88±0,54
the value of ΔL* shows "average value ± standard deviation" for 8 animals.

<Example 1: Example 1 of the preparation for external use on skin of the present invention >

Cosmetic preparation (lotion), which is a preparation for external use on skin of the present invention, prepared in accordance with the composition shown in Table 3. That is, the components of the preparation is heated to 80°C, stirred, dissolved and cooled with stirring to obtain Lotion 1. In the same way as above, prepare a lotion of Comparative example 1 by replacing the "compounds represented by the General formula (1) according to the present invention (Compound 3)" water.

Table 3
Component% of the mass.
"The connection represented by the General formula (1) according to the present invention (Compound 3)"0,5
POE (60) gidrirovannoe castor oil0,1
1,3-Butanediol5,0
Glycerin2,0
Polyethylene glycol3,0
1,2-Pentanediol3,0
Xanthan gum0,1
Potassium hydroxide0,05
Methylparaben0,2
Water86,05
Total100

<Example study 3: Inhibitory effects of cosmetic formulation (lotion) on pigmentation in humans caused by ultraviolet radiation >

Inhibitory effect on pigmentation of compound 3 are examined through the use of Lotion 1 drug and cosmetic of Comparative example 1. Two plots, each of which has a size of 1.5 cm ×1.5 cm, are selected on the secondary side of the shoulder of each voluntary participant in the research on the initial day (day 1) of study. Whiteness (L* values) of each of the study plots was measured with a colorimeter (CR-300, Konica Minolta Holdings, Inc.). After measurement of the skin white areas in the initial day of the study, the areas irradiated with ultraviolet radiation of twice the minimum dose that causes erythema (2 MED). Starting with feathers�th day after irradiation, 50 µl of each sample (lotion 1 and comparative example 1) is applied to specified areas of research three times a day for 14 consecutive days. 24 hours after completion of application (on the 15th day), whiteness (L* values) of each study area was measured using a colorimeter (CR-300, Konica Minolta Holdings, Inc.), and the value of ∆L* is calculated relative to the value L of the unprocessed area. Table 4 shows the results. When the degree of pigmentation becomes stronger, the value of ∆L* becomes smaller. For this reason, we can estimate that when the value of ∆L* becomes larger (high numerical value), pigmentation was inhibited stronger. This fact suggests that the lotion is 1, which is a preparation for external use on skin of the present invention has an excellent inhibitory effect on pigmentation. It is believed to be provided by the inhibitory effects of compounds represented by the General formula (1) according to the present invention (Compound 3) described above, the production of melanin.

/tr>
Table 4
The research samplethe value of ΔL*
Lotion 1-3,25
Comparative example 1-4,02

<Example 2: Example 2 of the preparation for external use on skin of the present invention >

Cream type water in oil prepared in accordance with the composition shown in Table 5. In particular, the components A and B is heated to 80°C, respectively, and component B is gradually added to the components A, followed by homogenization emulsification particles using a homogenizer for Cream 1. In the same way as above, the cream of Comparative example 2 prepared by replacing the "compounds represented by the General formula (1) according to the present invention (Compound 3)" water, and cream of Comparative example 3 prepared by replacing the "compounds represented by the General formula (1) according to the present invention (Compound 3)" arbutin.

Table 5
ComponentAndShares of mass.
Complex sucrose fatty acid ester0,5
Vaseline1,0
Lanolin3,0
Liquid paraffin8,0

Silicone low viscosity30,0
Stearyl alcohol0,5
Stearic acid0,55
Monoglyceride undecylenic acid2,0
Organically modified bentonite In2,0
1,3-Butanediol5,0
Glycerin20,0
"The connection represented by the General formula (1) according to the present invention (Compound 3)"0,5
Methylparaben0,2
Water26,6
Potassium hydroxide0,5
Polyglucosides methacrylate0,1
(molecular weight: about 100,000)
Total100

<Example study 4: the Inhibitory effects of cosmetic formulation (cream) on skin pigmentation in humans caused by ultraviolet radiation>

Investigate the inhibitory effect on pigmentation Cream 1 and cosmetic preparations of Comparative example 2 and Comparative example 3. Four sections, each of which has a size of 1.5 cm ×1.5 cm, divided into upper and lower section, respectively, are installed at located closer to the center side of the shoulder of each of the 10 voluntary research participants. The areas irradiated with ultraviolet radiation at a minimum dose of the occurrence of erythema (1 MED) once a day for 3 consecutive days, i.e., 3 times. After the third ultraviolet irradiation, 50 µl of each sample (Cream 1, comparative example 2 and comparative example 3) is applied to specified areas of research three times daily for 28 consecutive days. One area not treated. 24 hours after completion of application (on the 29th day), whiteness (L* values) of each area of research are measured using a colorimeter (CR-300, Konica Minolta Holdings, Inc.), and the value of ∆L* is calculated relative to the value L of the unprocessed area. When the degree of pigmentation becomes stronger, the value of L* mills�tsya less. For this reason, we can estimate that when the value of ∆L* becomes larger (high numerical value), pigmentation was inhibited stronger. Table 6 shows the results. These facts suggest that the Cream 1, which is a preparation for external use on skin of the present invention has an excellent inhibitory effect on pigmentation. It is believed to be provided by the inhibitory effects of compounds represented by the General formula (1) according to the present invention (Compound 3) described above, the production of melanin.

Table 6
The research samplevalueΔL*
Cosmetic product (Cream 1)0,93
Comparative example 20,12
Comparative example 30,35

Industrial application

The present invention can refer to a preparation for external use on the skin, including, for example, a cosmetic whitening agent for the skin.

1. Agent for the prevention or reduction of pigmentation, containing Conn�use, represented by the following General formula (1) and its stereoisomer and/or its pharmacologically acceptable salt:

[where:
R1represents a hydrogen atom or alkyl group with a linear or branched chain having 1-4 carbon atoms;
R2represents a hydrogen atom or unsubstituted aliphatic hydrocarbon group having 1-4 carbon atoms;
R3represents an unsubstituted aromatic group having 5-15 carbon atoms, a substituted alkyl group having 1-6 carbon atoms, alkoxy group containing an alkyl chain having 1-6 carbon atoms, or a phenyl group, an aromatic group having 5-15 carbon atoms;
n is an integer equal to 1 or 2, and m is an integer from 0 to 3].

2. Agent for preventing or reducing the pigmentation of claim 1, wherein in the General formula (1):
R1represents a hydrogen atom or alkyl group with a linear or branched chain having 1-4 carbon atoms;
R2represents a hydrogen atom;
R3represents an unsubstituted aromatic group having 5-15 carbon atoms, a substituted alkyl group having 1-6 carbon atoms, alkoxy group containing an alkyl chain having 1-6 carbon atoms, or a phenyl group,an aromatic group, having 5-15 carbon atoms;
n is an integer equal to 1 or 2, and m is an integer from 0 to 3.

3. Agent for preventing or reducing the pigmentation of claim 1, wherein in the General formula (1):
R1represents a hydrogen atom or alkyl group with a linear or branched chain having 1-4 carbon atoms;
R2represents a hydrogen atom;
R3represents an unsubstituted aromatic group having 5-15 carbon atoms, a substituted alkyl group having 1-6 carbon atoms, alkoxy group containing an alkyl chain having 1-6 carbon atoms, or a phenyl group, an aromatic group having 5-15 carbon atoms;
n is an integer 1 or 2 and m represents 0.

4. Agent for preventing or reducing the pigmentation of claim 1, wherein in the General formula (1):
R1represents a hydrogen atom or alkyl group with a linear or branched chain having 1-4 carbon atoms;
R2represents a hydrogen atom;
R3represents an unsubstituted aromatic group having 5-15 carbon atoms, a substituted alkyl group having 1-6 carbon atoms, alkoxy group containing an alkyl chain having 1-6 carbon atoms, or a phenyl group, an aromatic group having 5 to 15 carbon atoms�Yes;
n is 1 and m is 0.

5. Agent for preventing or reducing the pigmentation of claim 1, wherein the compound represented by the General formula (1) is a N-(o-toluoyl)cysteine acid (Compound 1), N-(m-toluoyl)cysteine acid (Compound 2), N-(p-toluoyl)cysteine acid (Compound 3), N-(p-methoxybenzoyl)cysteine acid (Compound 4), N-(4-phenylbenzyl)cysteine acid (Compound 5), N-(p-toluoyl)homocysteinemia acid (Compound 6), its stereoisomer and/or its pharmacologically acceptable salt:

N-(o-toluoyl)cysteine acid (Compound 1);

N-(m-toluoyl)cysteine acid (Compound 2);

N-(p-toluoyl)cysteine acid (Compound 3);

N-(p-methoxybenzoyl)cysteine acid (Compound 4)

N-(4-phenylbenzyl)cysteine acid (Compound 5);

N-(p-toluoyl)homocysteinemia acid (Compound 6).

6. The preparation for external use on the skin, containing the agent for the prevention or reduction of pigmentation according to claim 1.

7. The preparation for external use on skin according to claim 6, which contains from 0.001% wt. up to 20% of the mass. agent for the prevention or reduction of pigmentation in relation to the total amount of the drug d�I external use on the skin.

8. The preparation for external use on skin according to claim 6, where the preparation for external use on skin is a cosmetic product (provided that included preventive and curative cosmetics).

9. The preparation for external use on skin for skin whitening containing the compound represented by the General formula (1) and its stereoisomer and/or its pharmacologically acceptable salt.

10. A method of preventing or reducing pigmentation, comprising the step of applying the compounds represented by the following General formula (1), its stereoisomers and/or its pharmacologically acceptable salt, the entity for which the prevention or reduction of pigmentation should:

[where:
R1represents a hydrogen atom or alkyl group with a linear or branched chain having 1-4 carbon atoms;
R2represents a hydrogen atom, unsubstituted aliphatic hydrocarbon group having 1-4 carbon atoms;
R3represents an unsubstituted aromatic group having 5-15 carbon atoms, a substituted alkyl group having 1-6 carbon atoms, alkoxy group containing an alkyl chain having 1-6 carbon atoms, or a phenyl group, an aromatic group having 5-15 carbon atoms;
n is an integer equal to 1 or 2, and m is an integer from 0 to 3].



 

Same patents:
Hair care product // 2553347

FIELD: cosmetology.

SUBSTANCE: hair care product is made in the form of gel, shampoo, lotion. All embodiments comprise aqueous vegetable extracts, phosphonate complex containing potassium-sodium salts of oxyethylidenebisphosphonic acid or their mixture with trisodium salt hexahydrate of phosphonformic acid and a cosmetically acceptable base.

EFFECT: hair care product is recommended for use in medicinal and cosmetic purposes for all ages for prevention and treatment of dystrophic changes in hairy part of the head.

5 cl

FIELD: cosmetology.

SUBSTANCE: cosmetic product contains an aqueous solution of trace elements in amounts close to the daily demand of the human body, succinic acid which provides a high level of energy production (ATP), and also a bioregulatory complex obtained from hair follicles of calves, which stimulates proliferation of dormant cells of hair follicles.

EFFECT: increased efficiency of cosmetic product for complete prevention of hair loss caused by a wider range of reasons, and for partial or complete restoration of hair.

5 ex

FIELD: chemistry.

SUBSTANCE: group of inventions relates to a two-phase mouth wash liquid and a method for use thereof. The disclosed two-phase mouth wash liquid contains a hydrophilic phase, a hydrophobic phase, a hydrotrope and a preservative, wherein the preservative contains (i) sodium benzoate and (ii) potassium sorbate and/or methylisothiazolinone (MIT), and the hydrotrope component contains glycerine and/or propylene glycol. The mouth wash liquid contains (a) 0.05-0.11 wt % sodium benzoate and (b) 0.05-0.2 wt % potassium sorbate and/or 0.0005-0.01 wt % MIT. The hydrophilic phase of the mouth wash liquid can additionally contain cetylpyridinium chloride in amount of 0.01-0.1 wt %, wherein the disclosed method of improving oral health includes using an effective amount of said liquid in the mouth of a subject to reduce the level of cariogenic bacteria.

EFFECT: use of said combination of preservatives coupled with said hydrotrope provides good resistance to microbial contamination without any adverse effect on taste properties or appearance of the mouth was liquid.

12 cl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to organic chemistry and specifically to 5-benzyl-1,3-diazaadamantan-6-one derivatives of formula , where X is hydrogen (1a), methoxyl (1c) substitutes.

EFFECT: obtaining novel fragrant 5-benzyl-1,3-diazaadamantan-6-ones, which can be used in perfume compositions, as medicinal substances, repellents and as starting substances for producing novel 1,3-diazaadamantan derivatives.

6 ex

FIELD: chemistry.

SUBSTANCE: composition of preparation for teeth cleaning contains effective quantity of arginine in free form or in form of salt; abrasive substance, containing (i) natural sodium carbonate (NSC) with the average size of particles 3-7 mcm and moisture absorption 12-25 g/100 g and (ii) precipitated calcium carbonate (PCC) with the average particle size 1-5 mcm and water absorption higher than 25 g/100 g. Ratio of natural calcium carbonate to precipitated calcium carbonate constitutes from 1:2 to 1:3. Composition has pellicle cleaning ratio (PCR), at least, 70 and value of abrasivity of isotope-labelled dentin (RDA) lower than 140. Method of oral cavity care includes application of effective quantity of said composition in oral cavity of individual requiring it.

EFFECT: effective teeth cleaning and strengthening without injuring abrasive action, which makes it possible to apply it, in particular, for individuals with increased teeth sensitivity.

13 cl, 2 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: composition contains a) surface-active substances, including a salt of C10-16 alcohol ethoxylate sulphate, a betaine surface-active substance and alkylpolyglicoside, and b) a fatty C12-18 acid, constituting at least 15% of the total composition weight.

EFFECT: composition, possessing an increased viscosity and capable of producing a stable foam, is created.

10 cl, 1 tbl, 4 ex, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine, particularly to cosmetology, and describes a method for stabilising an anhydrous antiperspirant composition involving: (a) preparing a mixture of at least one substance having the antiperspirant action, containing a metal salt, and an anhydrous carrier for at least one substance possessing the antiperspirant action, wherein dissolved is at least one substance having the antiperspirant action, a carrier containing an eutectic mixture of carbamide and trimethylglycine; (b) heating this mixture for preparing the eutectic mixture of at least one substance having the antiperspirant action, and the anhydrous carrier.

EFFECT: invention can be used to reduce the body perspiration; the compositions can be applied by hands or with a package.

22 cl, 3 dwg, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a compound of formula such as below , wherein Z is oxygen; Y is hydrogen or a sequence as follows: -O-C(R4)-V-(C=O)-R5; V is oxygen; R1 and R4 are identically or independently hydrogen or a C1-4 alkyl; R2 and R5 are identically or independently a C1-10 alkyl.

EFFECT: these compounds can be applicable in therapy for treating pathologies or disorders related to the presence of Propionibacterium acnes, eg acne-like skin disorders.

5 cl, 2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed is emulsified composition for improvement of skin condition, which contains (A) 0.001-10 wt % of organic compound, which has two or more hydroxyl groups, inorganic value 220-450 and organic value 300-1000; (B) 0.001-10 wt % of organic compound, which has one hydroxyl group, inorganic value 100-200 and organic value 280-700; (C) 0.001-10 wt % of organic substance, represented by formula (2), in which R1 is C4-C30 hydrocarbon group; Z is methylene group, methane group or oxygen atom; X1, X2, X3 are hydrogen atom, hydroxyl group or acetoxy group; X4 is hydrogen atom, acetyl group or glyceryl group; each of R2 and R3 is hydrogen atom, hydroxyl group, hydroxymethyl group or acetoxymethyl group; R4 is C5-C60 hydrocarbon group; and R5 is hydrogen atom or hydrocarbon group, containing in total 1-30 carbon atoms; (D) (D) 0.00012-10 wt % of at least one compound, selected from group, consisting of non-ionic surface-active substance, which has polyoxyethylene group and HLB 10 or higher, ionic surface-active substance and sphingosine salt; (E) 0.003-15 wt % of at least one compound, selected from group, consisting of sugar alcohol, selected from group, consisting of erythritol, threitol, xylitol and mannitol, disaccharide and trisaccaride, and (F) water.

EFFECT: emulsion composition preserves water in skin for long time.

13 cl, 1 dwg, 18 tbl, 64 ex

FIELD: chemistry.

SUBSTANCE: present invention refers to developing brewing products. According to the invention, a method for preparing an extract of polyphenols as a result of brewage involves the stages: contacting partially purified beer with resin, which adsorbs polyphenols; desorbing polyphenols adsorbed on the resin contacting with partially purified beer; adsorbing polyphenols on the second resin different from the first one; the above second resin is hydrophobic and non-ionic; and desorbing polyphenols adsorbed on the second resin with using an organic solvent; implementing the method is ethylacetate-free. The invention also refers to the method for preparing the extract of polyphenols as a result of brewage that involves the following stages: contacting partially purified beer with hydrophobic and non-ionic resin, which adsorbs polyphenols; and desorbing polyphenols adsorbed on the resin used at the previous stage of contacting with using the organic solvent; a desorption product contains at least 0.85 g of polyphenols per one gram of a dry matter. The invention also refers to the extract of polyphenols prepared by the above method and containing catechin, epicatechin, thyrozol and ferulic acid. The invention also refers to a cosmetic product, a functional food product, a food additive, which contain the above extract of polyphenols in an effective amount. Also the invention provides using the above cosmetic product for skin moistening and/or ageing prevention or delay, using the extract of polyphenols for producing an antioxidant composition.

EFFECT: invention provides preparing the extract of ethylacetate-free and high-purity polyphenols.

19 cl, 23 dwg, 22 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new idebenone derivatives substituted by carboxylic acid with general formula I wherein R1 represents C2-C22 saccharic acid with a direct or branched chain, while two or more hydroxy groups are independently substituted by C1-C22 carboxylic acid, wherein the term 'branched' refers to one or more groups of a lower alkyl. The invention also refers to a formulation for skin treatment containing the above idebenone derivatives, a method of treating the skin changes by local applications with these idebenone derivatives, as well as to methods of synthesis thereof. When adding the idebenone derivatives according to the present invention into the formulations for local application, they possess the antioxidant action effective in treating the skin changes.

EFFECT: above idebenone derivatives have unexpectedly occurred to be effective in skin treatment, especially in relation to skin tolerance.

20 cl, 1 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmaceutics and represents composition for reducing injury caused by ultraviolet radiation, which includes one or more compounds selected from the group consisting of D-methionine and its salts.

EFFECT: invention provides creation of stable and safe composition, which can be applied daily.

10 cl, 37 ex, 7 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to the field of cosmetology. Described is a stable and safe antioxidant composition, which can be applied daily. In particular, described is the antioxidant composition, which contains one or more compounds, selected from the group, which consists of D-aspartic acid, its derivatives and/or its salts. The composition can be applied with the purpose of suppressing and/or relief of a skin condition. Conditions of skin can include, but are not limited by them, small wrinkles, rough skin, dry skin, skin cancer, skin allergy, skin inflammation, and light-sensitive dermatosis. The composition can be applied as a medication for the external application on the skin.

EFFECT: invention ensures an increase of the antioxidant effect of the composition.

4 cl, 5 dwg, 31 ex

FIELD: medicine.

SUBSTANCE: topical cosmetic composition effective for stimulating each of SIRT1, Gadd45b and SOD2, which contains a senna alata leaves extract, a great morinda leaves extract and a melon flesh extract taken in certain proportions. A method for the protection against or recovery of an oxidative injury involving administering the topical composition containing the senna alata leaves extract, the great morinda leaves extract and the melon flesh extract taken in certain proportions. The topical cosmetic or dermatological composition for stimulating each of SIRT1, Gadd45b and SOD2. Using the above composition for producing a drug preparation for treating the oxidative injury.

EFFECT: composition is effective for stimulating each of SIRT1, Gadd45b and SOD2.

8 cl, 1 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical and cosmetic industries and represents a composition for relieving an ultraviolet injury by post-irradiation administration of a composition containing one or more compounds specified in a group consisting of D-glutamic acid and/or its salts, and at least one acceptable additive.

EFFECT: invention provides effective relief of the ultraviolet skin injuries.

11 cl, 34 ex, 1 tbl, 8 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry and presents application of zeaxanthin per se or in combination with rutin or with spremidin, or as with rutin, and with spremidin, for treatment of irritability of hairy part of head skin, including chemical therapy-induced alopecia, androgenic alopecia and telogene with hair loss.

EFFECT: invention ensures extension of arsenal of means for treating disorders of hairy part of head skin.

20 cl, 23 ex, 4 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical composition in the form of a skin protection paste. The composition contains a film-forming agent representing poly(butyl methacrylate-co-methyl methacrylate), hydrocolloid, a filling agent, a softening agent and an alcoholic diluent in the certain proportions.

EFFECT: pharmaceutical composition has a prolonged shelf life and is able to ensure a uniform skin coverage which is characterised by the balanced characteristics of durability and flexibility.

3 cl, 2 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to a composition for reducing oxidative stress in the skin caused by sunlight or ultraviolet light. A chewable composition for reducing oxidative stress caused by sunlight or ultraviolet light (UVB) in the skin, containing vitamin C, vitamin E, green tea extract having the content of epigallocatechin (EGC) of at least 20%, and gallic acid in a certain amount. A method for preserving an individual's healthy skin in the oxidative process caused by sunlight or ultraviolet light involving the oral administration of the composition.

EFFECT: composition is effective for reducing oxidative stress in the skin caused by sunlight or ultraviolet light.

14 cl, 6 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to dermatocosmetology, and can be used in treatment of dehydrated involutionally changed face skin in women. For this purpose the first stage successive complex morphofunctional examination of state of moisture-holding structures of epidermal and dermal face skin layers with estimation of their dehydration degree is carried out. First, epidermal layer is examined. If indices of corneal layer moisture degree are lower than 30 conv.units CM, those of moisture-holding function of epidermis are higher than 13 gram/hour/m2, degree of relief is higher than 25 conv.units, wrinkling is higher than 20 conv.units, porosity is 23 conv.units, as well as presence of roughness and thinning of epidermis contours, reduction of its echogenesity, smoothing of boundary between epidermis and derma with absence of changes in dermal structures, structural and functional disorders of epidermis with expressed dehydration are diagnosed. After that, state of moisture-holding structures of dermal skin layer is analysed. Degree of its elasticity, presence or absence of homogeneity, thickness and state of dermoepidermal connection are determined. In case of value of dermal structure elasticity indexes lower than 50%, reduction of derma thickness below index value 1.67±0.381, detection of non-homogeneity of dermal structures, development of hypoechogenic zones, structural and functional disorders of derma with expressed dehydration are diagnosed. Then, correction of dehydrated involutionally changed skin is carried out. In case if structural and functional disorders of epidermis are present, preparation "Hyalrepair-07M/mesolift" with concentration of hyaluronic acid 2 mg/ml is introduced intradermally in dose 1 ml on face area 1 time per week, the course includes 5 procedures. In case if structural and functional disorders of derma and epidermis are present, preparation "Hyalrepair-02 bioreparant" with concentration of hyaluronic acid 14 mg/ml is introduced in dose 1 ml on face area 1 time per 3 weeks, the course includes 3 procedures.

EFFECT: method ensures obtaining stable and expressed therapeutic effect in case of introduction of hyaluronic acid preparations due to identification and taking into account determined parameters.

1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to application of ester compounds of benzoic acid, taken from group, which includes 1-phenylvinyl 4-methoxybenzoate; 1-(4-methoxyphenyl)-vinyl 4-tert-butyl benzoate, 1-(4-tert-butylphenyl)-vinyl 4-methoxybenzoate, 1-phenylvinyl 4-tert-butyl benzoate, 4-benzoyloxy-2-methoxybenzolsulphonic acid, 3-diethylaminophenyl benzoate and 3-(1-pyrrolidinyl) phenyl benzoate and 3-methoxy salicylate, as component for preparing composition for protection of human organism or animal or material from ultraviolet radiation, containing effective quantity at least one of claimed compounds, as component for preparing composition, which is characterised by progressive protection from UV radiation, depending on duration of sun influence and level of sun radiation, as component for preparing composition for individual hygiene, which is characterised by progressive protection from UV radiation, depending on duration of sun influence and level of sun radiation, as component for preparing industrial composition, which is characterised by progressive protection from UV radiation, depending on duration of sun influence and level of sun radiation, and as component for preparing composition, which at photo-regrouping shows quantity of obtained UV-B radiation.

EFFECT: invention also relates to composition for protecting human or animal organism or protection of material from ultraviolet radiation, contains effective quantity of at least one above mentioned ester compound of benzoic acid.

40 cl, 6 dwg, 33 ex

Hair care product // 2553347

FIELD: cosmetology.

SUBSTANCE: hair care product is made in the form of gel, shampoo, lotion. All embodiments comprise aqueous vegetable extracts, phosphonate complex containing potassium-sodium salts of oxyethylidenebisphosphonic acid or their mixture with trisodium salt hexahydrate of phosphonformic acid and a cosmetically acceptable base.

EFFECT: hair care product is recommended for use in medicinal and cosmetic purposes for all ages for prevention and treatment of dystrophic changes in hairy part of the head.

5 cl

Up!